- Issuer ticker
-
VRTX
- Reported as of
-
24 Feb 2026
- Net transaction value
-
-$583,871
- SEC form
-
4
- Accepted by SEC
-
26 Feb 2026, 18:06:58 UTC
Filing notes and source
Key filing fact
Mark E. Bunnage filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 26 Feb 2026.
Key facts
- This page summarizes Mark E. Bunnage's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2026, 18:06.
Change
- Previous filing in this sequence was filed on 19 Feb 2026.
- Current net transaction value: -$583,871.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0002100735
Primary reporting owner
Bunnage Mark E.
- Relationship
-
EVP, Chief Scientific Officer
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Tax liability
- Transaction value
- -$282,334
- Shares
- -582
- Change %
- -6.9%
- Price
-
$485.11
- Shares after
- 7,904
- Date
- 24 Feb 2026
- Ownership
- Direct
VRTX
transaction
Common Stock
Sale
- Transaction value
- -$301,537
- Shares
- -620
- Change %
- -7.8%
- Price
-
$486.35
- Shares after
- 7,284
- Date
- 25 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses
1 footnote